NACDS supported the efforts of members and in-state partners to amend B23-535. As originally introduced, the bill would have required warning labels on opioid prescriptions to be printed in a certain font and color scheme. The compromise amendment adopted during the Committee on Health markup removed the font and color mandate but still requires a warning label. The amended and engrossed version is expected to continue through the legislative process.
Also in the District of Columbia. B23-430, legislation allowing pharmacists to substitute interchangeable biologic products became effective on October 20 following the obligatory Congressional Review. Sponsored by Councilmember Mary Cheh (D) the law’s notification provisions are similar to those NACDS supported in other jurisdictions.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.